Sunday, September 13, 2026
ExploreSearch
Via News
MarketIndexes

Nikkei 225 Went Up By Over 5% In The Last 5 Sessions

ViaNews Editorial Team

October 12, 2023

Nikkei 225 Went Up By Over 5% In The Last 5 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 5.81% for the last 5 sessions. At 21:08 EST on Wednesday, 11 October, Nikkei 225 (N225) is $32,300.24.

About Nikkei 225's yearly highs and lows, it's 25.87% up from its 52-week low and 4.36% down from its 52-week high.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikkei 225's is considered to be oversold (<=20).

News about

  • According to FXStreet on Tuesday, 10 October, "The Dow Jones, S&P 500 and NASDAQ Composite have all advanced around half a percentage point, with the NASDAQ taking the lead."

More news about Nikkei 225 (N225).

Categories

MarketIndexes

Tags

IndexWorld IndicesIndicesN225Nikkei 225Price UpINDICES Price UpIndex Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Chip Boom Lifts Semiconductors as Export-Control Gaps Persist
AI infrastructure demand is fueling a broad semiconductor rally — Broadcom's AI chip revenue and Q4 guidance, Amazon's custom silicon crossing a $25B annual run rate, and bullish analyst calls on Micron and Sandisk tied to a memory chip boom underestimated even by bulls — with ASML rallying on sympathy. That momentum runs alongside unresolved US-China tech tensions: Belgium's arrest of a suspect for stealing chip technology for China and a blacklisted Chinese firm still acquiring Nvidia's top AI chips show export-control enforcement lagging the pace of AI chip demand.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com